OTLK INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OTLK
16 nov. 2023 14h09 HE
|
The Rosen Law Firm PA
NEW YORK, Nov. 16, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between December...
Axogen, Inc. Reports 2023 Third Quarter Financial Results
07 nov. 2023 07h00 HE
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Goliath Drills 23.65 Meters* of Abundant Visible Gold at Surebet Zone, Within Golden Gate Feeder Zone, Golddigger Property, Golden Triangle B.C.
19 sept. 2023 03h08 HE
|
Goliath Resources Limited
Drill Highlights: GD-23-226 intercepted a 23.65 meter* interval containing abundant Visible Gold included within 30.98 meters of wide strongly mineralized quartz breccia and stockwork. This...
Axogen to Participate at Upcoming Investor Conferences
31 août 2023 07h00 HE
|
Axogen, Inc.
ALACHUA and TAMPA, Fla., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today...
Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio
21 août 2023 07h00 HE
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
14 août 2023 16h15 HE
|
Checkpoint Therapeutics, Inc
Biologics License Application for cosibelimab under review by U.S. FDA; Successful mid-cycle meeting with U.S. FDA completed; PDUFA goal date of January 3, 2024 Longer-term cosibelimab results...
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IBRX
27 juil. 2023 11h33 HE
|
The Rosen Law Firm PA
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between May 23, 2022 and...
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IBRX
21 juil. 2023 22h25 HE
|
The Rosen Law Firm PA
NEW YORK, July 21, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between May 23, 2022 and May...
Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)
20 juin 2023 08h00 HE
|
Aridis Pharmaceuticals, Inc.
LPAD may provide alternative pathways for streamlined product approval LOS GATOS, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical...
Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
15 mai 2023 16h15 HE
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...